A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy
Study of Ampreloxetine in Treating Orthostatic Hypotension in Multiple System Atrophy (MSA)
Sponsor: Theravance Biopharma
Enrolling: Male and Female Patients
Study Length: 124 Months
Clinic Visits: 12
IRB Number: AAAU6952
U.S. Govt. ID: NCT05696717
Contact: Haidyn Emmerich: 929-445-0329 / he2281@cumc.columbia.edu
Additional Study Information: You may be eligible to take part in the study because you have a diagnosis of Multiple System Atrophy (MSA) with the symptoms of neurogenic Orthostatic Hypotension (nOH). MSA is a rare disorder in adults that progresses rapidly and ultimately is a fatal neurodegenerative disease. It is characterized by autonomic failure affecting blood pressure regulation, movement and balance. Autonomic failure occurs when the autonomic nervous system, which controls functions responsible for well-being and maintaining balance, does not regulate properly. The main purpose of this study is to look at Ampreloxetine (referred to as the study drug) and assess its efficacy in treating nOH symptoms in people with MSA.
Sheng-Han Kuo, MD
Do You Qualify?
Have you been diagnosed with MSA-C or MSA-P? Yes No
Are you currently taking high blood pressure (antihypertensive) medications? Yes No
Have you had a neurological event within the past 6 months (i.e., seizures, confusion, altered levels of consciousness, etc.) ? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Haidyn Emmerich